Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY:XBI)

109.56 -0.61 (-0.55%)
Official Closing Price Updated: 4:10 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,790,107
Open 110.13
Bid (Size) 109.15 (12)
Ask (Size) 109.50 (12)
Prev. Close 110.17
Today's Range 109.08 - 110.53
52wk Range 66.66 - 110.96
Shares Outstanding 541,500
Dividend Yield 0.10%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga

Performance

YTD
+19.7%
+19.7%
1 Month
+12.6%
+12.6%
3 Month
+27.6%
+27.6%
6 Month
+45.1%
+45.1%
1 Year
+11.6%
+11.6%

More News

Read More
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral
Via Stocktwits
4 Biotech Stocks Seeing Explosive Momentum Gains
Via Benzinga
Topics ETFs Stocks
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report
Via Stocktwits
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline
Via Benzinga
Topics ETFs Government
SciSparc And AutoMax Call Off Merger
Via Benzinga
Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma
Via Stocktwits
Topics Government
Pharma Tariffs Back In Spotlight On New Trump Threat
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial
Via Stocktwits
CrowdStrike, SoFi, Clearway Energy And More: CNBC's 'Final Trades'
Via Benzinga
Topics ETFs Stocks
As the Fed Pivots, These 3 ETFs Are Positioned to Outperform
Via The Motley Fool
Topics ETFs Economy
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Via Benzinga
Topics ETFs Government
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
Via Investor's Business Daily
Topics ETFs Economy Government
Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages
Via Stocktwits
Topics ETFs Intellectual Property
Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning
Via Stocktwits
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Via Stocktwits
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
Via Stocktwits
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
Via Stocktwits
Topics Lawsuit Regulatory Compliance
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
Via Stocktwits
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
Via Benzinga
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
Via Investor's Business Daily
Topics ETFs Government

Frequently Asked Questions

Is SPDR Series Trust SPDR S&P Biotech ETF publicly traded?
Yes, SPDR Series Trust SPDR S&P Biotech ETF is publicly traded.
What exchange does SPDR Series Trust SPDR S&P Biotech ETF trade on?
SPDR Series Trust SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF?
The ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of SPDR Series Trust SPDR S&P Biotech ETF?
The current price of SPDR Series Trust SPDR S&P Biotech ETF is 109.56
When was SPDR Series Trust SPDR S&P Biotech ETF last traded?
The last trade of SPDR Series Trust SPDR S&P Biotech ETF was at 10/21/25 04:10 PM ET
What is the market capitalization of SPDR Series Trust SPDR S&P Biotech ETF?
The market capitalization of SPDR Series Trust SPDR S&P Biotech ETF is 59.33M
How many shares of SPDR Series Trust SPDR S&P Biotech ETF are outstanding?
SPDR Series Trust SPDR S&P Biotech ETF has 59M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.